PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery
Clinical trial NCT04295317 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04295317
- Sponsor
- Shanghai Zhongshan Hospital
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-08-01
- Primary completion
- 2025-06-01
- Enrollment
- 65
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.